A Model Based Approach to Robustness Analysis and Optimisation of Chromatography Processes
(2006)- Abstract
- One of the major issues in the pharmaceutical industry today is the cost of development and validation of the production of the active pharmaceutical ingredients. The development, optimization and validation of a production plant have been dominated by an extensive experimental approach.
The large amount of experimental work and reluctance for changing existing processes has caused the pharmaceutical companies to develop fewer pharmaceuticals and at higher cost today compared to the previous decades. The United States Food and Drug Administration (FDA) has recognised this tendency and realised that they are one part of the problem causing the pharmaceutical companies to be less profitable with fewer new drugs on the... (More) - One of the major issues in the pharmaceutical industry today is the cost of development and validation of the production of the active pharmaceutical ingredients. The development, optimization and validation of a production plant have been dominated by an extensive experimental approach.
The large amount of experimental work and reluctance for changing existing processes has caused the pharmaceutical companies to develop fewer pharmaceuticals and at higher cost today compared to the previous decades. The United States Food and Drug Administration (FDA) has recognised this tendency and realised that they are one part of the problem causing the pharmaceutical companies to be less profitable with fewer new drugs on the market. As a first step to contribute to the modernisation of the pharmaceutical industry the FDA launched a guideline for implementation of Process Analytical Technologies (PAT).
A model based methodology provides means to interpret experimental results and formulate them as process knowledge. The ability to predict process behaviour makes it possible to more easily design an operating point that combines process economy and robustness. The impact of process variations can be predicted and measures can be taken to compensate for the impact on the quality of the output.
The present work focuses on ion exchange and hydrophobic interaction chromatography and the column behaviour is described by using a kinetic dispersive model, where the steric mass action or langmuir MPM model accounts for the adsorption. This work strives at presenting a model based methodology to efficiently utilise the experimental work normally conducted at the development laboratories to determine a suitable operating point and to determine the robustness of that point. Another contribution is the implementation of robust design where process variations and model error is incorporated into the design to ensure a robust operating point. (Less) - Abstract (Swedish)
- Popular Abstract in Swedish
Kostnaden för utveckling och validering av produktionsanläggningar är idag ett stort problem för farmaceutisk industri. Valideringen innebär normalt en stor experimentell arbetsinsats. Den stora mängden experimentellt arbete innebär att det utvecklas färre läkemedel och till högre kostnad idag jämfört med tidigare. FDA har uppmärksammat detta i sitt PAT initiativ.
En modellbaserad metodik kan minska den experimentella bördan och vara ett sätt att formalisera processkunskap. Detta arbete handlar i huvudsak om jonbytes kromatografi och kromatografi som baserar sig på hydrofobiska interaktioner och en modellbaserad metodik. Metodiken an användas för att utnyttja det experimentella... (More) - Popular Abstract in Swedish
Kostnaden för utveckling och validering av produktionsanläggningar är idag ett stort problem för farmaceutisk industri. Valideringen innebär normalt en stor experimentell arbetsinsats. Den stora mängden experimentellt arbete innebär att det utvecklas färre läkemedel och till högre kostnad idag jämfört med tidigare. FDA har uppmärksammat detta i sitt PAT initiativ.
En modellbaserad metodik kan minska den experimentella bördan och vara ett sätt att formalisera processkunskap. Detta arbete handlar i huvudsak om jonbytes kromatografi och kromatografi som baserar sig på hydrofobiska interaktioner och en modellbaserad metodik. Metodiken an användas för att utnyttja det experimentella arbetet mera effektivt för att hitat en lämplig driftspunkt med avseende på både robusthet och processekonomi. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/546465
- author
- Jakobsson, Niklas LU
- supervisor
- opponent
-
- PhD, Manager Protein Purification Staby, Arne, Novo Nordisk
- organization
- publishing date
- 2006
- type
- Thesis
- publication status
- published
- subject
- keywords
- Kemiteknik och kemisk teknologi, Chemical technology and engineering, Langmuir, SMA, Optimisation, Robustness, Chromatography, Prepartive/process scale, Modelling
- pages
- 71 pages
- publisher
- Department of Chemical Engineering, Lund University
- defense location
- Room A, Chemical centre,Getingevägen 60, Lund Institute of Technology
- defense date
- 2006-05-24 13:15:00
- external identifiers
-
- other:ISRN: LUTKDA/(TKKA-1001)/1-71/(2006)
- ISBN
- 978-91-628-6769-0
- language
- English
- LU publication?
- yes
- id
- ef1543bf-c0cc-4298-b713-b1957686480e (old id 546465)
- date added to LUP
- 2016-04-01 15:57:50
- date last changed
- 2018-11-21 20:37:42
@phdthesis{ef1543bf-c0cc-4298-b713-b1957686480e,
abstract = {{One of the major issues in the pharmaceutical industry today is the cost of development and validation of the production of the active pharmaceutical ingredients. The development, optimization and validation of a production plant have been dominated by an extensive experimental approach.<br/><br>
<br/><br>
The large amount of experimental work and reluctance for changing existing processes has caused the pharmaceutical companies to develop fewer pharmaceuticals and at higher cost today compared to the previous decades. The United States Food and Drug Administration (FDA) has recognised this tendency and realised that they are one part of the problem causing the pharmaceutical companies to be less profitable with fewer new drugs on the market. As a first step to contribute to the modernisation of the pharmaceutical industry the FDA launched a guideline for implementation of Process Analytical Technologies (PAT).<br/><br>
<br/><br>
A model based methodology provides means to interpret experimental results and formulate them as process knowledge. The ability to predict process behaviour makes it possible to more easily design an operating point that combines process economy and robustness. The impact of process variations can be predicted and measures can be taken to compensate for the impact on the quality of the output.<br/><br>
<br/><br>
The present work focuses on ion exchange and hydrophobic interaction chromatography and the column behaviour is described by using a kinetic dispersive model, where the steric mass action or langmuir MPM model accounts for the adsorption. This work strives at presenting a model based methodology to efficiently utilise the experimental work normally conducted at the development laboratories to determine a suitable operating point and to determine the robustness of that point. Another contribution is the implementation of robust design where process variations and model error is incorporated into the design to ensure a robust operating point.}},
author = {{Jakobsson, Niklas}},
isbn = {{978-91-628-6769-0}},
keywords = {{Kemiteknik och kemisk teknologi; Chemical technology and engineering; Langmuir; SMA; Optimisation; Robustness; Chromatography; Prepartive/process scale; Modelling}},
language = {{eng}},
publisher = {{Department of Chemical Engineering, Lund University}},
school = {{Lund University}},
title = {{A Model Based Approach to Robustness Analysis and Optimisation of Chromatography Processes}},
year = {{2006}},
}